MedTrace Logo

The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy

NCT06318507 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-02-17

No results posted yet for this study

Summary

This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.

Conditions

  • Breast Neoplasms

Interventions

COMBINATION_PRODUCT

Fecal microbial diversity

Fecal microbiome diversity via 16S rRNA and metagenomic sequencing

Sponsors & Collaborators

  • Pennington Biomedical Research Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06318507 on ClinicalTrials.gov